

Ocrevus Zunovo

(ocrelizumab and hyaluronidase)

Treatment Location: _____

PROVIDERS: Please include the following to expedite the order:

Patient Demographics, Insurance Information, All Clinical Documentation Supporting the Diagnosis, Including Any Previous or Current Therapies, Pertinent Labs, or Diagnostic Testing, Recent Labs Including Hep B Results, Serum Immunoglobulins, Liver Function Tests

PATIENT INFORMATION

Referral Status: ☐ New Referral ☐ Updated Order ☐ Order Renewal ☐ Home Infusion

Patient Name: _____ Patient Phone: _____ DOB: _____

ICD-10 code (required): ☐ G35.A ☐ G35.B1 ☐ G35.B2 ☐ G35.C1 ICD Description: _____

Allergies: _____ Weight (lbs/kg): _____ Height: _____

Patient Status: ☐ New to Therapy ☐ Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

PROVIDER INFORMATION

Referral Coordinator Name: _____ Referral Coordinator Email: _____

Ordering Provider: _____ Provider NPI: _____

Referring Practice Name: _____ Phone: _____ Fax: _____

Practice Address: _____ City: _____ State: _____ Zip: _____

NURSING

- ☒ Center will use Hypersensitivity protocol established by Infusion for Health and PI
- ☒ Hep B (HBsAb and anti-HBc) Test Results (list & attach clinicals): _____
- ☒ Serum Immunoglobulins (list results & attach clinicals) _____
- ☒ Liver Function (ALT, AST, Alkaline Phosphatase, Bilirubin) Test Results (list results and attach clinicals) _____

PRE-MEDICATION ORDERS

It is recommended to pre-medicate with oral Dexamethasone or an equivalent corticosteroid and an antihistamine (eg desloratadine) approximately 30 minutes prior to each injection.

- ☐ Dexamethasone ☐ 20mg PO
- ☐ Claritin ☐ 10mg PO
- ☐ Acetaminophen ☐ 325mg / ☐ 500mg / ☐ 650mg PO
- Other: _____
- Dose: _____ Route: _____ Frequency: _____

SPECIAL INSTRUCTIONS:

LABORATORY ORDERS

- ☐ CBC ☐ at each dose ☐ every _____
- ☐ CMP ☐ at each dose ☐ every _____
- ☐ Ig Panel ☐ at each dose ☐ every _____
- ☐ Urine Pregnancy ☐ at each dose ☐ every _____
- ☐ Other: _____ ☐ Frequency: _____
- ☐ Please check this box if you DO NOT authorize Infusion for Health to order and draw labs indicated for clinical clearance and/or insurance authorization prior to treatment.

THERAPY ADMINISTRATION

- ☒ Ocrevus Zunovo SQ Injection
Dose: 920 mg/23,000 units hyaluronidase/23 mL administered subcutaneously in the abdomen over 10 minutes
Frequency: Every 6 months
- ☐ Monitor patients for 1 hour after the completion of initial injection and for 15 minutes after subsequent injections.
- ☐ Refills: ☐ Zero / ☐ for 12 months / ☐ _____
(if not indicated order will expire one year from date signed)

To ensure that a brand name product is dispensed, the prescriber must handwrite "Brand Medically Necessary" on the prescription form. If not indicated, I4H is authorized to administer a generic or biosimilar.

Provider Name (Print) _____ Provider Signature _____ Date _____

- ☐ Please check this box if you DO NOT authorize Infusion for Health to complete a Peer to Peer on behalf of the prescribing provider for an insurance company that denies authorization for treatment.